Jianing Yi*, Shuai Chen*, Pingyong Yi†, Jinlin Luo*, Meng Fang*, Yang Du*, Lianhong Zou*, Peizhi Fan*
Oncology Research, Vol.28, No.5, pp. 519-831, 2020, DOI:10.3727/096504020X15960154585410
Abstract 5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for breast cancer. However, acquired chemoresistance leads to a loss of its efficacy; methods to reverse are urgently needed. Some studies have shown
that pyrotinib, an ErbB receptor tyrosine kinase inhibitor, is effective against HER2+
breast cancer. However,
whether pyrotinib sensitizes 5-FU-resistant breast cancer cells to 5-FU is unknown. We hypothesized that the
combination of pyrotinib and 5-FU would show synergistic antitumor activity, and pyrotinib could reverse
5-FU resistance in HER2+
breast cancer cells in vitro and in vivo. Our data showed that pyrotinib inhibited
the growth of 5-FU-resistant SKBR-3/FU and MDA-MB-453/FU… More >
Login
Register
